Source link : https://www.newshealth.biz/health-news/dramatic-phase-2-results-for-survodutide-in-mash-fibrosis/
MILAN — Survodutide, an investigational dual glucagon-like peptide 1 (GLP-1) and glucagon receptor agonist, led to “exceptional improvement in disease activity and fibrosis” in patients with metabolic dysfunction–associated steatohepatitis (MASH), according to phase 2 results presented here at the European Association for the Study of the Liver (EASL) Congress 2024. The data were simultaneously published […]
Author : News Health
Publish date : 2024-06-12 11:56:27
Copyright for syndicated content belongs to the linked Source.
Categories